Rituximab or biosimilar clinical trials

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

This study looks at a new drug, BIVV020, to help people who have had a kidney transplant. It aims to see if it can stop their body from rejecting the new kidney or treat rejection if it happens. The study tests how well it works and if it's safe.